ArticleClinical, cosmetic and investigational dermatology2026
Diverging Incidence and Mortality of Cutaneous Melanoma in Mainland China, 1990-2023, with Projections to 2030: A Global Burden of Disease 2023 Analysis.
Article in Clinical, cosmetic and investigational dermatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To quantify changes in incidence, prevalence, mortality, and disability-adjusted life-years (DALYs) from cutaneous melanoma in mainland China, assess demographic drivers, and project age-standardized rates to 2030 using Global Burden of Disease (GBD) 2023 estimates. Methods: We extracted annual estimates for 1990-2023 by sex and 5-year age group. Estimated annual percentage changes summarized age-standardized rate trends. Decomposition separated changes in absolute burden into population growth, population aging, and epidemiological change, defined as residual changes in age-specific rates after demographic effects. Bayesian age-period-cohort models projected age-standardized rates to 2030. Results: From 1990 to 2023, incident cases increased from 4,657 to 16,593, and prevalent cases increased from 15,401 to 102,526. The age-standardized incidence rate increased from 0.49 to 0.79 per 100,000, and the age-standardized prevalence rate increased from 1.39 to 5.03 per 100,000, with estimated annual percentage changes of 1.39% and 4.14%, respectively. In contrast, the age-standardized mortality rate declined from 0.33 to 0.27 per 100,000, and the age-standardized DALY rate declined from 9.74 to 7.54 per 100,000. The burden shifted toward older ages, although the largest absolute numbers of cases and DALYs clustered around ages 55-59 years. Aging contributed most to rising incident cases and DALYs, whereas epidemiological change drove prevalence expansion and partly offset DALY growth. By 2030, the combined-sex age-standardized incidence and prevalence rates were projected to reach 0.88 and 5.84 per 100,000, respectively, while mortality was projected to remain nearly stable and the DALY rate to decline slightly. Conclusion: Cutaneous melanoma in mainland China remains uncommon but rising incidence and prevalence, alongside declining age-standardized mortality and DALY rates indicate a changing burden profile. This divergence may increase demand for longitudinal services, but it does not demonstrate improved individual survival or chronicity. Strengthened early detection, age-adapted prevention, standardized diagnosis, and long-term survivorship care are needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.